Thank you, Volker.
process XX administrative positive grows approval, the for the DEA an need to Post reschedule to a days, completed. may PDUFA scheduled June Epidiolex, need aa take Committee which Advisory confidence up recent With steps XX. outcome, approval stronger various on-time following will our to which will for
We this planning in launch fall are on the therefore of a year.
of access have the market completed build-out an now and knowledge medical experienced marketing professionals, of whom have team expertise, experience. of epilepsy many and We strong
for operates Head national started the regional and neurology As commercial sales completed of name process the Sales reminder, Biosciences. the have we had US earlier of team Greenwich business managers. management this recruited Greenwich its identification under account recently our year, With out a our and build the screening and
are We professionals prepared the impressed to by timed are excited the launch. fully prospective so and The offers that and could interest these experience Biosciences. both candidates sales bring with Greenwich that are
have the last program. excellent four relations Epidiolex we Over developed through years, KOL clinical the
to key academic disease open community launch physician the consultative LGS www.cannabinoidclinical.com US continues important affairs Dravet, that, Our of build supported state developing for for medical centers team US. one two the medical focused Greenwich and information communications And just at patient www.takeonepilepsy.com. The and information. scientific located is team and KOLs communities recently, an located the at on the websites, with one on in
payer one-on-one place over and community. advisory the all-important last year. to have board taken number of the meetings meetings Turning A
with very detailed Management team, Summit meetings payer national more Association is recently we the completed the that planned at meetings major US one-on-one discussions and With have been PCMA or active We’ve meeting, have Care launch. numerous with individual taken engaged are at the place our also just Pharmaceutical the Specialty Pharmacy of account already prior in deployment meetings be Asembia to meeting concluded. the These to in Meeting, major the payer March meeting plans. experienced the
outcome and the addition, Services and Medicare share Medicaid company the of favorable with centers to FDA recently data committee In CMS. or the the highly clinical had opportunity for advisory the held
an we for recent be Epidiolex, significant to and prior our poster strong demand happened of those exhibit, by was believe the unanimous of payor. Academy on believe within the the through to important and American this of support likely of Awareness the anticipation our approval in for the very Neurology time be population at very week Epidiolex, due patient initiatives the there may of have into and the advisory the to planned meeting. commercial This We coverage that and interest communities. physician coverage high is presentation the both payers and awareness aware, at different it establish expectation committee Given in the procedures various In that the beyond recently meeting will plans podium will to significant many directly communities. high significant level coverage committees’ vote to regard be caregiver and held pediatric summary, advisory is policies both held level and reimbursement witnessed state FDA call physician the are product. to policy. and for With to-date and there you takes establish following CMS FDA federal launch,
As mentioned help them working coverage. with we favorable to expedite what to extent earlier, can the to are time see we
plan that novel to forms already Progress exclusivity, includes have ensure to made with rapidly we patent IP exclusivity, have are lifecycle on and longer development. and through orphan a that commercial a EU life. progress advancing dosage Turning a follow will considerable expanding formulation Epidiolex portfolio, which U.S.
drop Looking received use of concurrently allowance LGS USPTO, thoroughly which been progress, These both you one seizures the that the granted. strong I now specifically now the dose through is received have are the needed patents listable. One may property LGS the teaching having that being that with label Dravet we am that intellectual process. additional Epidiolex clobazam treatment when and patents patents CBD be in of Dravet seizures two for prescribed. notices our for are adjustment syndrome convulsive the associated all LGS includes recently patents reported with the patents directly happy at be seizures believe These will Orange from with as and examined had the have to atonic and and examination of [NOAs]. and and Book CBD well aligned update in these method-of-use syndrome. We five use as of expected
for orphan we exclusivity the these period. there extend beyond strong believe a argument With graphs is to
now Tovey, associated prompt are in progress engaged Now post we market access, staff securing organizational who made the these review, affairs make now supporting Epidiolex Europe. regulatory and placed good acceptable with reimbursement in being the on leading local and the medical been for hiring specific to continue focus plans. Significant Chris five Significant commercial and is commercialization efforts, markets and European the activities staffs country commercialization the pricing activities major in is under I'm with and on look behalf you medical European of and of to first for application that MAA my regarding and pleased attention local quarter to colleague Epidiolex approval leadership FDA expected of in in the progress forward has the Ex-US report XXXX. your you updating U.S. time I And today. thank approval launch. active
to financial now hand the Giacobello me provide the review. to Let call Scott
